Spero Therapeutics
SPRO
60 hedge funds and large institutions have $24.6M invested in Spero Therapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 23 closing their positions.
69% more call options, than puts
Call options by funds: $382K | Put options by funds: $226K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 69 → 60 (-9)
29.14% less ownership
Funds ownership: 56.61% → 27.47% (-29%)
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
37% less capital invested
Capital invested by funds: $39.3M → $24.6M (-$14.7M)
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.89M |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$647K |
| 3 |
Millennium Management
New York
|
+$351K |
| 4 |
Renaissance Technologies
New York
|
+$239K |
| 5 |
Two Sigma Investments
New York
|
+$74.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$6.81M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$3.86M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.87M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1M |
| 5 |
BlackRock
New York
|
-$381K |
SPRO Hedge Fund Activity: Q4 2022 in Review
60 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2022, worth a combined $24.6M — down 37% from $39.3M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SPRO and 14 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 11 added.
The largest buyer was Anson Funds Management, adding an estimated $2.89M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $6.81M sold.
- 60 institutional investors held Spero Therapeutics (SPRO) as of Q4 2022, down from 69 in Q3 2022.
- Funds reported $24.6M of Spero Therapeutics stock for Q4 2022, down 37% quarter-over-quarter.
- 14 funds opened new Spero Therapeutics positions in Q4 2022 and 23 closed out, a net change of -9 holders.
- The largest Spero Therapeutics buyer in Q4 2022 was Anson Funds Management, an estimated $2.89M added.
- The largest Spero Therapeutics seller in Q4 2022 was Aquilo Capital Management, an estimated $6.81M sold.
Based on aggregated 13F filings for Q4 2022.